China's drug industry accelerates AI-driven deal-making

China's pharmaceutical sector is increasingly leveraging artificial intelligence to discover and develop new drug candidates, aiming to fuel a new wave of domestic and international deals. The nation is already a significant player in global drug development, contributing about 30% of new therapies worldwide. Recent collaborations, such as the one between CSPC Pharmaceutical Group and AstraZeneca, highlight the growing trend of using AI-powered platforms for drug discovery. AI

IMPACT Accelerates drug discovery timelines and potentially increases the volume of pharmaceutical M&A activity.

RANK_REASON Significant industry trend in AI adoption for drug discovery and deal-making. [lever_c_demoted from significant: ic=1 ai=0.7]

Read on SCMP — Tech →

• artificial intelligence
• AstraZeneca
• China
• CSPC Pharmaceutical Group
• Lan Gongtao
• National Medical Products Administration

• product
• funding

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →